175 related articles for article (PubMed ID: 33238530)
1. The Predictive Value of Low Skeletal Muscle Mass Assessed on Cross-Sectional Imaging for Anti-Cancer Drug Toxicity: A Systematic Review and Meta-Analysis.
Huiskamp LFJ; Chargi N; Devriese LA; May AM; Huitema ADR; de Bree R
J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33238530
[TBL] [Abstract][Full Text] [Related]
2. Low skeletal muscle mass is a predictor of treatment related toxicity in oncologic patients. A meta-analysis.
Surov A; Pech M; Gessner D; Mikusko M; Fischer T; Alter M; Wienke A
Clin Nutr; 2021 Oct; 40(10):5298-5310. PubMed ID: 34536638
[TBL] [Abstract][Full Text] [Related]
3. Prognostic Role of Low-Skeletal Muscle Mass on Staging Computed Tomography in Metastasized Colorectal Cancer: A Systematic Review and Meta-Analysis.
Meyer HJ; Strobel A; Wienke A; Surov A
Clin Colorectal Cancer; 2022 Sep; 21(3):e213-e225. PubMed ID: 35792019
[TBL] [Abstract][Full Text] [Related]
4. CT-defined low-skeletal muscle mass as a prognostic marker for survival in prostate cancer: A systematic review and meta-analysis.
Meyer HJ; Wienke A; Surov A
Urol Oncol; 2022 Mar; 40(3):103.e9-103.e16. PubMed ID: 34483042
[TBL] [Abstract][Full Text] [Related]
5. Low Skeletal Muscle Mass Predicts Relevant Outcomes in Palliative Urological Oncology: A Systematic Review and Meta-Analysis.
Meyer HJ; Wienke A; Zamsheva M; Surov A
Urol Int; 2023; 107(3):219-229. PubMed ID: 36455534
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and mortality risk of low skeletal muscle mass in critically ill patients: an updated systematic review and meta-analysis.
Yang H; Wan XX; Ma H; Li Z; Weng L; Xia Y; Zhang XM
Front Nutr; 2023; 10():1117558. PubMed ID: 37252244
[TBL] [Abstract][Full Text] [Related]
7. Low skeletal muscle mass predicts treatment response in oncology: a meta-analysis.
Surov A; Strobel A; Borggrefe J; Wienke A
Eur Radiol; 2023 Sep; 33(9):6426-6437. PubMed ID: 36929392
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and role of low skeletal muscle mass (LSMM) in hepatocellular carcinoma. A systematic review and meta-analysis.
March C; Omari J; Thormann M; Pech M; Wienke A; Surov A
Clin Nutr ESPEN; 2022 Jun; 49():103-113. PubMed ID: 35623801
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and Effect of Low Skeletal Muscle Mass among Hepatocellular Carcinoma Patients Undergoing Systemic Therapy: A Systematic Review and Meta-Analysis.
Kuo MH; Tseng CW; Hsu CS; Chen YC; Kao IT; Wu CY; Shao SC
Cancers (Basel); 2023 Apr; 15(9):. PubMed ID: 37173893
[TBL] [Abstract][Full Text] [Related]
10. Low skeletal muscle mass and treatment outcomes among adults with haematologic malignancies: A systematic review and meta-analysis.
Anabtawi NM; Pasala MS; Grimshaw AA; Kharel P; Bal S; Godby K; Siwakoti A; Buford TW; Bhatia S; Costa LJ; Williams GR; Giri S
J Cachexia Sarcopenia Muscle; 2024 Jun; 15(3):1084-1093. PubMed ID: 38558541
[TBL] [Abstract][Full Text] [Related]
11. Low skeletal muscle mass as a risk factor for postoperative delirium in elderly patients undergoing colorectal cancer surgery.
Mosk CA; van Vugt JLA; de Jonge H; Witjes CD; Buettner S; Ijzermans JN; van der Laan L
Clin Interv Aging; 2018; 13():2097-2106. PubMed ID: 30425464
[TBL] [Abstract][Full Text] [Related]
12. Sarcopenia as a Prognostic Marker for Survival in Gastric Cancer Patients Undergoing Palliative Chemotherapy. A Systematic Review and Meta Analysis.
Meyer HJ; Wienke A; Surov A
Nutr Cancer; 2022; 74(10):3518-3526. PubMed ID: 35603926
[TBL] [Abstract][Full Text] [Related]
13. Computed tomography-defined low skeletal muscle mass as a prognostic marker for short-term mortality in critically ill patients: A systematic review and meta-analysis.
Meyer HJ; Wienke A; Surov A
Nutrition; 2021; 91-92():111417. PubMed ID: 34399402
[TBL] [Abstract][Full Text] [Related]
14. Computed tomography-defined body composition as prognostic markers for unfavourable outcomes and in-hospital mortality in coronavirus disease 2019.
Meyer HJ; Wienke A; Surov A
J Cachexia Sarcopenia Muscle; 2022 Feb; 13(1):159-168. PubMed ID: 35018725
[TBL] [Abstract][Full Text] [Related]
15. Association of low skeletal muscle mass with advanced liver fibrosis in patients with non-alcoholic fatty liver disease.
Kang MK; Park JG; Lee HJ; Kim MC
J Gastroenterol Hepatol; 2019 Sep; 34(9):1633-1640. PubMed ID: 30667551
[TBL] [Abstract][Full Text] [Related]
16. The IMPACT study: early loss of skeletal muscle mass in advanced pancreatic cancer patients.
Basile D; Parnofiello A; Vitale MG; Cortiula F; Gerratana L; Fanotto V; Lisanti C; Pelizzari G; Ongaro E; Bartoletti M; Garattini SK; Andreotti VJ; Bacco A; Iacono D; Bonotto M; Casagrande M; Ermacora P; Puglisi F; Pella N; Fasola G; Aprile G; Cardellino GG
J Cachexia Sarcopenia Muscle; 2019 Apr; 10(2):368-377. PubMed ID: 30719874
[TBL] [Abstract][Full Text] [Related]
17. Skeletal muscle mass is associated with toxicity, treatment tolerability, and additional or subsequent therapies in patients with hepatocellular carcinoma receiving sorafenib treatment.
Sawada K; Saitho Y; Hayashi H; Hasebe T; Nakajima S; Ikuta K; Fujiya M; Okumura T
JGH Open; 2019 Aug; 3(4):329-337. PubMed ID: 31406927
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of low skeletal muscle mass compared with protein-energy malnutrition in liver cirrhosis.
Nishikawa H; Enomoto H; Ishii A; Iwata Y; Miyamoto Y; Ishii N; Yuri Y; Takata R; Hasegawa K; Nakano C; Nishimura T; Yoh K; Aizawa N; Sakai Y; Ikeda N; Takashima T; Iijima H; Nishiguchi S
Hepatol Res; 2017 Sep; 47(10):1042-1052. PubMed ID: 27862791
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of low skeletal muscle mass in hepatocellular carcinoma patients treated with sorafenib or lenvatinib: A meta-analysis.
Guan J; Yang Q; Chen C; Wang G; Zhu H
EXCLI J; 2021; 20():1-16. PubMed ID: 33510588
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
